Background drugs and low maraviroc levels explain resistance in Motivate studies
1 February 2008. Related: Conference reports, Drug resistance.
Drug resistance
Dual-class mutations affection RTI and NNRTI may be common in experienced patients
1 February 2008. Related: Drug resistance.
Integrase inhibitors and resistance
7 July 2007. Related: Conference reports, Drug resistance.
Treatment failure and tropism changes in maraviroc trial related to previously undetected CXCR4, rather than a mutational shift from CCR5
3 July 2007. Related: Conference reports, Drug resistance.
Mechanisms of failure to CCR5 inhibitors is not explained by mutation in the V3 loop, cross-resistance between CCR5 inhibitors is likely
3 July 2007. Related: Conference reports, Drug resistance.
Higher risk of resistance using lopinavir/r monotherapy
3 July 2007. Related: Conference reports, Drug resistance.
Macaque study shows similar protection from rectal exposure using 2-hour pre- and 24-hour post exposure prophylaxis with tenofovir plus FTC compared to daily regimen
3 July 2007. Related: Conference reports, Drug resistance.
Thirteen NNRTI mutations linked to resistance to etravirine (TMC-125)
3 July 2007. Related: Conference reports, Drug resistance.
Few integrase inhibitor (INI) mutations in INI-naive people
4 May 2007. Related: Conference reports, Drug resistance.
Response to darunavir, tipranavir, or lopinavir after atazanavir failure
4 May 2007. Related: Conference reports, Drug resistance.
Upper and lower clinical cutoffs proposed for darunavir
4 May 2007. Related: Conference reports, Drug resistance.
Accuracy of Monograms Trofile assay in determining tropism and new tropism assays in development
4 May 2007. Related: Conference reports, Drug resistance.
Several genotyping systems offer hope as tropism predictors
4 May 2007. Related: Conference reports, Drug resistance.
Raltegravir (MK-0518) phase 3 trials show successful viral suppression in multi-drug resistant patients
4 April 2007. Related: Conference reports, Antiretrovirals, Drug resistance.
Unexpectedly high rate of K65R mutation in patients failing first-line d4T-containing regimens in Thailand
4 April 2007. Related: Conference reports, Drug resistance.
Multi-drug resistance in vertically infected children
6 December 2006. Related: Conference reports, Paediatric care, Drug resistance.
MK-0518 demonstrates potent efficacy in patients with triple-class resistant virus: 24 week results
7 October 2006. Related: Conference reports, Drug resistance.
Cell studies predict cross-resistance among integrase inhibitors
7 October 2006. Related: Conference reports, Drug resistance.
Report from the 10th Annual UK Resistance Meeting, 21 September 2006, London
7 October 2006. Related: Conference reports, Drug resistance.
15th International Drug Resistance Workshop, 13-17 June 2006, Sitges, Spain
3 August 2006. Related: Conference reports, Drug resistance.
Resistance implications of monotherapy with lopinavir/r (Kaletra)
3 August 2006. Related: Conference reports, Drug resistance.
Ritonavir reduces virological failure and resistance in treatment naive patients treated with atazanavir
3 August 2006. Related: Conference reports, Drug resistance.
Resistance to darunavir (TMC-114): predicting responses for treatment experienced patients
3 August 2006. Related: Conference reports, Drug resistance.
Epidemiological studies and transmission of resistance: evidence for optimism or issues with interpretation?
3 August 2006. Related: Conference reports, HIV prevention and transmission, Drug resistance.
K103N containing variants persist longer in women with subtype D and with higher viral loads
3 August 2006. Related: Conference reports, Drug resistance.
No subtype-based differences in baseline levels of K103N-containing variants in women receiving single dose nevirapine
3 August 2006. Related: Conference reports, Drug resistance.
Phenotypic NNRTI resistance and genetic diversity in antiretroviral naive women
3 August 2006. Related: Conference reports, Drug resistance.
High prevalence of the K65R mutation in Botswana patients treated with ddI/d4T-based regimens
3 August 2006. Related: Conference reports, Drug resistance.
Potential for easier selection of K65R mutation with tenofovir pressure in subtype C HIV-1 isolates
3 August 2006. Related: Conference reports, Drug resistance.
Categorisation of transmitted HIV drug resistance using the WHO/CDC HIV drug resistance threshold survey method may be useful in resource limited settings
3 August 2006. Related: Conference reports, Drug resistance.
Limitations in online tools to identify HIV-1 subtypes
3 August 2006. Related: Conference reports, Drug resistance.
Resistance implications from PrEP and microbicide studies in macaques
3 August 2006. Related: Conference reports, Drug resistance.
Low-level resistance linked to treatment failure: a role for more sensitive testing for naive patients
3 August 2006. Related: Conference reports, Drug resistance.
Testing for resistance after starting treatment
3 August 2006. Related: Conference reports, Drug resistance.
Web resources for HIV-1 genotypic-resistance test interpretation
10 June 2006. Related: Drug resistance.
Association between HIV subtype and detection of K103N
13 April 2006. Related: Conference reports, Pregnancy, Drug resistance.
Cost effectiveness of resistance testing for treatment-naive patients
13 December 2005. Related: Drug resistance.
Highlights of HIV drug resistance studies presented at the 3rd IAS Conference
13 October 2005. Related: Conference reports, Drug resistance.
Interaction between tenofovir and ddI in triple-nucleoside combinations: role of M184V in explaining resistance on failure
14 July 2005. Related: Conference reports, Drug resistance.
Predicting clinical responses to ddI from genotypic resistance
14 July 2005. Related: Conference reports, Drug resistance.
Under-detection of transmission of transmitted resistance and impact on treatment response
14 July 2005. Related: Conference reports, Drug resistance.
Risk of death in UK after diagnosis of 3-class resistance
14 July 2005. Related: Conference reports, Drug resistance.
Tenofovir, nucleosides, and non-nucleosides
15 May 2005. Related: Conference reports, Drug resistance.
Protease inhibitors
15 May 2005. Related: Conference reports, Drug resistance.
CCR5 antagonists
15 May 2005. Related: Conference reports, Drug resistance.
Another chance for 3TC in patients with M184V mutation?
6 September 2004. Related: Conference reports, Antiretrovirals, Treatment strategies, Drug resistance.
Risk of NNRTI-resistance during STI: implications for SMART and other STI studies
29 July 2004. Related: Conference reports, Drug resistance.
Persistent nevirapine resistance following mother to child transmission interventions
29 July 2004. Related: Conference reports, Pregnancy, Drug resistance.
Tipranavir resistance and viral response: L90M did not reduce response, recommendation to use with T-20
29 July 2004. Related: Conference reports, Pregnancy, Drug resistance, Other news.
Resistance in the UK: new approach to epidemiological studies
29 July 2004. Related: Conference reports, Drug resistance.
Low AZT activity against HIV-2 infection
29 July 2004. Related: Conference reports, Drug resistance.
No evidence for cross resistance between nevirapine and d4T
29 July 2004. Related: Conference reports, Drug resistance.
Experimental compounds to target viral expression in latent cells
29 July 2004. Related: Conference reports, Antiretrovirals, Drug resistance.
Case of MDR reinfection with MDR virus
29 July 2004. Related: Conference reports, Drug resistance.
Kaletra therapy fails woman with subtype C virus with multiple mutations
2 June 2004. Related: Drug resistance.
Understanding developments in HIV drug resistance for new drugs and targets — atazanavir, fusion (T-20) and receptor inhibitors
2 May 2004. Related: Conference reports, Drug resistance.
Summary of resistance studies at Retrovirus
3 April 2004. Related: Conference reports, Drug resistance.
XII International HIV Drug Resistance Workshop, Los Cabos, Mexico, 10-14 June 2003
1 September 2003. Related: Conference reports, Drug resistance.
Transmission of drug resistance – at 11% in Europe and 17% in the UK
1 September 2003. Related: Conference reports, HIV prevention and transmission, Drug resistance.
HIV coinfection, reinfection and superinfection
1 September 2003. Related: Conference reports, Hepatitis coinfection, HIV prevention and transmission, Drug resistance.
Single-dose nevirapine resistance in over 75% of mothers
1 September 2003. Related: Conference reports, Women's health, Pregnancy, Drug resistance.
Transmission of drug resistant virus does not revert to wild-type and does not appear ‘less fit’
1 September 2003. Related: Conference reports, Drug resistance.
Standard genotype assays may miss 75% of mutations when present in less than 35% of plasma sample
1 September 2003. Related: Conference reports, Drug resistance.
Low-level resistance and minority populations: cross resistance between nevirapine and efavirenz occurs even in the absence of genotypic mutations found using population sequencing
1 September 2003. Related: Conference reports, Drug resistance.
Persistent effect of d4T and 3TC, but not NNRTIs in the presence of associated genotypic mutations
1 September 2003. Related: Conference reports, Drug resistance.